Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[124I]mIBG PET/CT vs [123I]mIBG in Metastatic Neuroblastoma
NCT02043899Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Feb 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-124 metaiodobenzylguanidine in neuroblastoma, sponsored by Cancer Research UK. Primary endpoint: Comparison of the Number of Lesions Detected as Positive by [123I]mIBG Planar Scintigraphy Which Are Also Considered Positive With [124I]mIBG PET/CT at Day 1. Started Feb 2014; status: completed.
02
Drugs
iodine-124 metaiodobenzylguanidine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02043899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043899.